Psychedelic Inspired Medicines

We are pioneering medicines that have the potential to maintain the therapeutic benefits of psychedelics, without the hallucinogenic effects.

Experience Modern Mind Care

with Psychedelic Inspired Medicines

Derived from psychedelics

zero to negligible hallucination effect

Prescribed by a Doctor

in accordance with diagnosis, for the purpose of healing

Picked up at a Pharmacy

at-home use with daily or weekly administration

Addiction is a Brain Disease

21 million Americans have at least one addiction, yet despite focused efforts in the space, which are saving lives on a daily basis, only 10% of those individuals receive treatment4.  Addiction is a brain disease, driven by a set of disease processes including the dysregulation of dopamine, a potent neurotransmitter, in the brain’s reward/pleasure center located in the midbrain.

Developing 18-MC to Treat the Cause of the Brain Disease that is Addiction

We are developing 18-MC to treat the cause of the brain disease that is addiction, rather than solely the symptoms. Sustained mental healing requires addressing a root cause and a comprehensive approach for the entire patient journey.

Cue-induced reinstatement, or relapse,  is when an individual with a substance use disorder is prompted by their surroundings to consume a harmful substance (example: The clink of a wine glass at a dinner party for a person with an alcohol use disorder).

Our intent is to develop and deploy a treatment that can solve for one of the most common and challenging aspects of substance use disorders, cue-induced relapse

JR Rahn

Cofounder & Chief Executive Officer of MindMed

Advancing the “Antibiotic of Addiction”


Dr. Stanley Glick (Scientific Advisor) invented 18-MC as a solution for addiction.

18-MC: The Next-Gen Version of Ibogaine

The Need for a Safer Ibogaine

Ibogaine is a Schedule 1 substance extracted from the West Africa iboga shrub with anti-addictive properties but has potential to induce heart attacks

Our Solution

Our scientists and chemists have invented a better version of ibogaine, a derivative called 18-MC

18-MC for Treating Addiction

Designed to correct the dysregulation in the brain’s reward/pleasure center to treat addiction without the hallucinogenic and potential negative side effects of ibogaine

MindMed’s approach to addiction is predicated on the understanding that while there have been substantial strides in treating some substance use disorders, more tools are desperately needed to help people in need. We recognize that there remain multiple use disorders without any currently approved treatments.”

Dan Karlin

Chief Medical Officer

Generation Adderall Has Grown Up

10M

Adult suffering in US from ADHD5

10.9%

Adults with ADHD who are receiving treatment6

+123%

Between 2007 and 2016 alone, the rate amongst adults increased by 123%. 7

While ADHD is often associated with children and adolescents, adults living with the disease face numerous challenges from debilitating struggles with time management and impulsivity to mood swings and disorganization.

Existing medicines to treat ADHD can be highly addictive themselves and have dangerous long term effects on health. Many people do not get treatment, and many prefer to suffer versus taking the risks associated with treatment.

Microdosing for Macro Healing

Microdosing refers to a smaller, non-hallucinogenic dose of LSD. In these cases, the medicinal properties of the compound address the illness and may not require a hallucinogenic dose as a component of healing.

Extensive anecdotal evidence suggests microdosing Psilocybin & LSD may:

  • Increase focus
  • Decrease anxiety
  • Increase creativity
  • Improve mood

Rigorous scientific trials are in progress to validate these claims and ensure the highest standards of quality, safety, and efficacy for medical use if approved. This is where MindMed’s Microdosing Division comes in.

Clinical Trial Progress

Learn more about clinical collaborations with Dr. Matthias Liechti & Liechti Lab at University Hospital Basel (Switzerland) and Dr. Kim Kuypers, the leading global expert in the clinical science of Microdosing, at Maastricht University (Netherlands)